Klinikum Oldenburg AöR
- Address
- lock Available on a paid plan
Klinikum Oldenburg AöR - Comprehensive Cancer & Specialty Research Center
Klinikum Oldenburg AöR is a leading medical research institution specializing in oncology and hematology, with extensive expertise across multiple cancer types and therapeutic approaches. The center demonstrates particular strength in blood cancer research, including acute leukemias, lymphomas, and multiple myeloma, while maintaining active programs in solid tumors and inflammatory conditions.
- Hematologic malignancies including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma, and various lymphoma subtypes (DLBCL, mantle cell lymphoma, Hodgkin lymphoma, CNS lymphoma)
- Breast cancer research encompassing triple-negative breast cancer, hormone receptor-positive/HER2-negative early breast cancer, and neoadjuvant/adjuvant therapeutic strategies
- Gastrointestinal cancers including colorectal cancer with genetic abnormalities (BRAF mutations), rectal cancer with novel treatment approaches, and biliary tract cancer
- Dermatological conditions and autoimmune diseases including moderate-to-severe plaque psoriasis, atopic dermatitis, lupus erythematosus variants, hidradenitis suppurativa, and prurigo nodularis
The center's research portfolio reflects a commitment to precision medicine and targeted therapies, with extensive investigation of novel immunotherapies, antibody-drug conjugates, and molecularly-targeted agents. Pediatric oncology represents another significant focus area, with studies in childhood leukemia, lymphoblastic lymphoma, rhabdomyosarcoma, Ewing sarcoma, germ cell tumors, and ependymoma. The institution also conducts important cardiovascular research, including studies on calcific aortic valve stenosis and post-operative atrial fibrillation following cardiac surgery, demonstrating its multidisciplinary expertise across therapeutic domains.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 9 therapeutic areas and 15 of 142 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 141 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 30 by active trials.
- 1GPOH gGmbH5active
lock +29 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH5trials
lock +23 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Oldenburg AöR
lock Showing 1 of 85 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis | Novartis Pharma AG | Phase II | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 142 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 12 | Unknown | 2017-07-12 | 2024-10-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.